Scott Depee

Inhibition of colony-stimulating-factor-1 signaling <i>in vivo</i> with the orally bioavailable cFMS kinase inhibitor GW2580

James G. Conway, Brad McDonald, Janet H. Parham et al. · Proceedings of the National Academy of Sciences · 2005 · 252 citations · Full text

Life Sciences, Pharmacology, Bone Metabolism +14

Effects of the cFMS Kinase Inhibitor 5-(3-Methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in Normal and Arthritic Rats

James G. Conway, Heather M. Pink, Mandy L. Bergquist et al. · Journal of Pharmacology and Experimental Therapeutics · 2008 · 55 citations

Medicine, Medicinal Chemistry, Pharmacology +9

Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.

S. Gail Eckhardt, Sharyn D. Baker, John R. Eckardt et al. · PubMed · 1998 · 36 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor

CJH Gerrits, JHM Schellens, G.J. Creemers et al. · British Journal of Cancer · 1997 · 25 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +9

A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion

Luis Paz‐Ares, Robert L. Kunka, D Demaria et al. · British Journal of Cancer · 1998 · 23 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13